Mechelen, Belgium; 18 September 2013 - Galapagos NV (Euronext: GLPG) announced
today that its Board of Directors has created and offered 75,000 warrants under
a new warrant plan.
On 18 September 2013, the Board of Directors of Galapagos approved the "Warrant
Plan 2013Â (B)" within the framework of the authorized capital. Â Under this
warrant plan, 75,000 warrants were created (subject to acceptance) and offered
to David Smith, who joined Galapagos' Executive Committee as CEO of the service
division.
These warrants have an exercise term of eight years as of the date of the offer
and have an exercise price of €15.18 (the average closing price of the share on
Euronext Brussels during the thirty days preceding date of the offer). Â The
warrants are not transferable and can in principle not be exercised prior to the
end of the third calendar year after the calendar year in which they were
granted. Â Each warrant gives the right to subscribe to one new Galapagos share.
 Should the warrants be exercised, Galapagos will apply for the listing of the
resulting new shares on a regulated stock market. Â The warrants as such will not
be listed on any stock market.
To date, Galapagos' total share capital amounts to €160,962,030.82; the total
number of securities conferring voting rights is 29,755,302, which is also the
total number of voting rights (the "denominator"), and all securities conferring
voting rights and all voting rights are of the same category. Â The total number
of rights (warrants) to subscribe to not yet issued securities conferring voting
rights is 3,636,015, which equals the total number of voting rights that may
result from the exercise of these warrants.
About Galapagos
Galapagos (Euronext: GLPG; OTC: GLPYY) is specialized in novel modes-of-action,
with a large pipeline of five Phase 2 (two led by GSK), one Phase 1, six pre-
clinical, and 20 discovery small-molecule and antibody programs in cystic
fibrosis, inflammation, antibiotics, metabolic disease, and other indications.
GLPG0634 is an orally-available, selective inhibitor of JAK1 for the treatment
of rheumatoid arthritis and potentially other inflammatory diseases, currently
in Phase 2B studies in RA and about to enter Phase 2 studies in Crohn's
disease. AbbVie and Galapagos signed a worldwide license agreement whereby
AbbVie will be responsible for further development and commercialization after
Phase 2B. Galapagos has another selective JAK1 inhibitor in Phase 2 in lupus
and psoriasis, GSK2586184 (formerly GLPG0778, in-licensed by GlaxoSmithKline in
2012). GLPG0974 is the first inhibitor of FFA2 to be evaluated clinically for
the treatment of IBD; this program is currently in a Proof-of-Concept Phase 2
study. GLPG1205 is a first-in-class molecule that targets inflammatory
disorders and is currently in a First-in-Human Phase 1 study.
The Galapagos Group, including fee-for-service companies BioFocus, Argenta and
Fidelta, has around 800 employees and operates facilities in five countries,
with global headquarters in Mechelen, Belgium. Further information at:
www.glpg.com
Contact
Galapagos NV
Elizabeth Goodwin, Director Investor Relations
Tel: +31 6 2291 6240
ir@glpg.com
Galapagos forward-looking statements
This release may contain forward-looking statements, including, without
limitation, statements containing the words "believes," "anticipates,"
"expects," "intends," "plans," "seeks," "estimates," "may," "will," "could,"
"stands to," and "continues," as well as similar expressions. Such forward-
looking statements may involve known and unknown risks, uncertainties and other
factors which might cause the actual results, financial condition, performance
or achievements of Galapagos, or industry results, to be materially different
from any historic or future results, financial conditions, performance or
achievements expressed or implied by such forward-looking statements. Given
these uncertainties, the reader is advised not to place any undue reliance on
such forward-looking statements. These forward-looking statements speak only as
of the date of publication of this document. Galapagos expressly disclaims any
obligation to update any such forward-looking statements in this document to
reflect any change in its expectations with regard thereto or any change in
events, conditions or circumstances on which any such statement is based, unless
required by law or regulation.
Galapagos creates new warrant plan:
http://hugin.info/133350/R/1729957/578054.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Galapagos NV via Thomson Reuters ONE
[HUG#1729957]